ABSTRACT
On June 16, 2023, National Disease Control and Prevention Administration of the People’s Republic of China, in collaboration with other ministries, formulated and issued the Action Plan to Accelerate the Elimination of Schistosomiasis in China (2023—2030). The implementation of this plan provides an important basis for achieving the targets set in the “Healthy China 2030” action plan and the implementation of the rural revitalization strategy. This paper describes the background, principles, targets, control strategies, safeguard measures and effectiveness evaluation of the plan, in order to guide the scientific and standardized implementation of actions for schistosomiasis elimination at the grassroots level, and facilitate the progress towards elimination of schistosomiasis in China with a high quality.
ABSTRACT
Objective To investigate the clinical efficacy of simvastatin combined with ferulate in treatment of early diabetic nephropathy (DN).Methods 106 patients with DN were randomly divided into two groups by random number table,and each group had 53 cases.The control group was given simvastatin,while the observation group was given simvastatin combined with ferulate,and the clinical outcomes were compared between the two groups.Results The total effective rate of the observation group was 92.45％,which was significantly higher than 73.58％ of the control group(x2 =8.992,P ＜ 0.05) ; after treatment,the Upro,SCr,BUN and CRP levels of the observation group were (50.72 ± 7.74) mg/24h,(70.01 ± 8.56) μmol/L,(3.87 ± 0.54) mmol/L and (3.51 ± 0.63) mmol/L,which were significantly lower than (83.74 ± 7.92) mg/24h,(84.33 ± 9.01) μmol/L,(5.03 ± 0.62) mmol/L and (5.52 ± 0.61) mmol/L of the control group,the difference was statistically significant (t =7.73,6.59,8.62,9.30,all P ＜ 0.05).Conclusion Simvastatin combined with ferulate in treatment of early diabetic nephropathy (DN) has significant effect,and it can effectively improve the clinical symptoms and protect renal function,and it has better clinical value.